Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population
The role of DNA repair gene polymorphisms in cancer development, progression, and response to treatment has received increased attention. We conducted a prospective study to determine whether associations exist between two polymorphisms in XRCC1 and ADPRT and the outcomes of Chinese ovarian cancer patients treated with platinum-based chemotherapy. A total of 335 new cases of ovarian cancer were consecutively collected between May 2005 and May 2007. Follow-up lasted for 4 years, and the outcome measure was survival time. Individuals carrying XRCC1 194Trp/Trp had a longer survival time than did those with the Arg/Arg genotype. Similarly, those carrying XRCC1 399 Gln/Gln genotypes had 0.44-fold the risk of death than those with the Arg/Arg genotype. The combination of XRCC1 194 Trp allele and 399 Gln allele could decrease the death risk of ovarian cancer. In summary, this study is the first to evaluate the associations between polymorphisms in DNA repair gene polymorphism and the risk of ovarian cancer in Chinese population. Our study found a significant association between XRCC1 Arg399Gln and XRCC1 Arg194Trp polymorphism and the clinical outcome of ovarian cancer. Furthermore, studies with larger sample sizes are still needed to confirm these associations in Chinese population.
KeywordsOvarian cancer XRCC1 ADPRT Polymorphism Chinese population
We thank the Chinese Medical Sciences University for the great help provided by its staff. This study was supported by the Natural Science Foundation of Tianjin (08JCYBJC05500).
Conflict of Interest
The authors report no conflicts of interest.
- 1.Ries LAG, Young JL, Keel GE et al (2007) SEER program, NIH Pub. No. 07-6215. National Cancer Institute, BethesdaGoogle Scholar
- 4.Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, Hedayati M, Grossman L, Mohrenweiser H, Wei Q (2002) Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 23:295–299. doi: 10.1093/carcin/23.2.295 PubMedCrossRefGoogle Scholar
- 5.Kudo K, Gavin E, Das S, Amable L, Shevde LA, Reed E (2012) Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum–DNA adduct repair. Oncogene. doi: 10.1038/onc.2011.610
- 9.Takabatake R, Koiwa T, Kasahara M, Takashima K, Futo S, Minegishi Y, Akiyama H, Teshima R, Oguchi T, Mano J, Furui S, Kitta K (2011) Interlaboratory validation of quantitative duplex real-time PCR method for screening analysis of genetically modified maize. Shokuhin Eiseigaku Zasshi 52:265–269. doi: org/10.3358/shokueishi.52.265
- 11.Oguchi T, Onishi M, Minegishi Y, Kurosawa Y, Kasahara M, Akiyama H, Teshima R, Futo S, Furui S, Hino A, Kitta K (2009) Development of quantitative duplex real-time PCR method for screening analysis of genetically modified maize. Shokuhin Eiseigaku Zasshi 50:117–125. doi: org/10.3358/shokueishi.50.117
- 13.Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D (2000) ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89:453–457. doi: 10.1002/1097-0215(20000920)89:5<453:AID-IJC9>3.3.CO;2-5 PubMedCrossRefGoogle Scholar
- 15.Krivak TC, Darcy KM, Tian C et al (2011) Single nucleotide polymorphisms in ERCC1 are associated with disease progression and survival in patients with advanced stage ovarian and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 122:121–126. doi: 10.1016/j.ygyno.2011.03.027 PubMedCrossRefGoogle Scholar
- 24.Hsieh YY, Chang CC, Chen SY, Chen CP, Lin WH, Tsai FJ (2012) XRCC1 399 Arg-related genotype and allele, but not XRCC1 His107Arg, XRCC1 Trp194Arg, KCNQ2, AT1R, and hOGG1 polymorphisms, are associated with higher susceptibility of endometriosis. Gynecol Endocrinol 28:305–309PubMedCrossRefGoogle Scholar
- 27.Saadat M, Mohammadynejad P, Ghanizadeh A, Saadat I (2012) Genetic polymorphisms (at codons 194 and 399) in the DNA repair gene XRCC1 and susceptibility to bipolar disorder. Psychiatry Res. doi: 10.1016/j.psychres.2012.01.021
- 33.Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, Kang SB (2009) Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 113:264–269. doi: 10.1016/j.ygyno.2009.01.002 PubMedCrossRefGoogle Scholar
- 34.Godoy H, Mhawech-Fauceglia P, Beck A, Miller A, Lele S, Odunsi K (2011) Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. Int J Gynecol Pathol 30:139–144. doi: 10.1097/PGP.0b013e3181fa5a64 PubMedCrossRefGoogle Scholar
- 39.Zhang Z, Miao XP, Tan W, Guo YL, Zhang XM, Lin DX (2006) Correlation of genetic polymorphisms in DNA repair genes ADPRT and XRCC1 to risk of gastric cancer. Chinese J Canc 25:7–10Google Scholar